Bharat Book

Chronic Plaque Psoriasis - Pipeline Review, H2 2013

Press Release   •   Dec 07, 2013 10:56 IST

Dec 07, 2013 : Bharat Book Bureau presents the new report, on 'Chronic Plaque Psoriasis - Pipeline Review, H2 2013'  also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis. Chronic Plaque Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Chronic Plaque Psoriasis.
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Eli Lilly and Company
GlaxoSmithKline plc
Biotest AG
Merck & Co., Inc.
AbGenomics International, Inc.
Novartis AG
Actelion Ltd
Eisai Co., Ltd.
Pfizer Inc.
Incyte Corporation
OPKO Health, Inc.
Can-Fite BioPharma Ltd.
Almirall, S.A.

Table of contents :

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Plaque Psoriasis Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chronic Plaque Psoriasis 8
Chronic Plaque Psoriasis Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Chronic Plaque Psoriasis Therapeutics - Products under Development by Companies 14
Companies Involved in Chronic Plaque Psoriasis Therapeutics Development 15
Eli Lilly and Company 15
GlaxoSmithKline plc 16
Biotest AG 17
Merck & Co., Inc. 18
AbGenomics International, Inc. 19
Novartis AG 20
Actelion Ltd 21
Eisai Co., Ltd. 22
Pfizer Inc. 23
Incyte Corporation 24
OPKO Health, Inc. 25
Can-Fite BioPharma Ltd. 26
Almirall, S.A. 27
Chronic Plaque Psoriasis - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ixekizumab - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
tofacitinib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
baricitinib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
tregalizumab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ponesimod - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
AbGn-168H - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
E-6201 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
briakinumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
adalimumab - Drug Profile 48
Product Description 48
Mechanism of Action 48

For more information kindly visit :

Related link :

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: 
Follow us on linked in : 
Our Blog : 

Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.